Disease Markers

The Discovery of Nucleotide and Nucleic Acid-Associated Biomarkers and Cancer Personalized Therapies 2022


Publishing date
01 Feb 2023
Status
Published
Submission deadline
07 Oct 2022

Lead Editor
Guest Editors

1Xi’an Jiaotong University, Xi'an, China

2University of Münster, Münster, Germany

3Sun Yat-Sen University, Guangzhou, China


The Discovery of Nucleotide and Nucleic Acid-Associated Biomarkers and Cancer Personalized Therapies 2022

Description

For half a century, cancer physicians have mainly relied on three primary treatment modalities: surgery, radiation therapy, and chemotherapy. Over that time, enormous progress has been made in understanding cancer biology. Targeted anti-cancer drugs have emerged, and thousands of clinical trials have taught us how to best craft treatment combinations that improve clinical outcomes.

However, each case of cancer exhibits a unique pathological signature and can be highly heterogeneous in response to the targeted therapeutic agents. Therefore, precise therapy is essential to improve cancer treatment. The development of personalized and rationalized therapy relies on the identification of the specific biomarkers, the validation of therapeutic targets, and the development of drugs against the validated targets. Nucleotide and Nucleic acid-associated biomarkers cover nucleotides, circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), mRNA, microRNAs (miRNAs), circular RNA (circRNA), exosomal RNAs (exRNAs), and long non-coding RNAs (IncRNAs) in tumor cells and serum. They are playing vital roles as diagnostic or therapeutic agents for cancer theranostics and can be used for cancer risk assessment, diagnosis, prognosis, and for the prediction of treatment efficacy and recurrence. In addition, the sensitive biomarkers can be also used as therapeutic targets for various tumors. Therefore, there is an urgent need to identify novel biomarkers and explore the biological functions of these biomarkers in order to greatly improve the clinical targeted therapies and immunotherapies of cancers.

This Special Issue aims to focus on the advances in the discoveries of nucleotide and nucleic acid-associated cancer biomarkers that inform treatment outcomes, including technologies and experimental approaches, as well as clinical validations and applications. We welcome the submission of original research and review articles.

Potential topics include but are not limited to the following:

  • New technologies or methods employed in characterizing molecular features of nucleotide and nucleic acid-associated biomarkers
  • cfDNA or ctDNA as biomarkers for cancer theranostics
  • circRNA, lncRNA, miRNA, or exRNAs as biomarkers for cancer theranostics
  • Regulatory roles of IncRNAs in tumorigenesis
  • The molecular mechanisms involved in the dysregualtion of nucleotide and nucleic acid-associated biomarkers in normal and pathological conditions
  • Nucleic acid-related biomarkers to predict the chemotherapy or immunotherapy response in cancer patients
  • Nucleotide regulation and metabolism in cancers
  • Other new emerging areas involving in nucleotide and nucleic acid-associated biomarkers, such as cross-analysis of biomarkers with nanomedicine, molecular imaging, omics data, etc.

Articles

  • Special Issue
  • - Volume 2023
  • - Article ID 9820901
  • - Retraction

Retracted: Exogenous Hydrogen Sulfide Mitigates Oxidative Stress and Mitochondrial Damages Induced by Polystyrene Microplastics in Osteoblastic Cells of Mice

Disease Markers
  • Special Issue
  • - Volume 2023
  • - Article ID 5493415
  • - Research Article

Identification of Inflammatory Gene in the Congenital Heart Surgery Patients following Cardiopulmonary Bypass via the Way of WGCNA and Machine Learning Algorithms

Liang Cai | Bingdong Zhang
  • Special Issue
  • - Volume 2023
  • - Article ID 7620181
  • - Research Article

A Comprehensive and Systematic Analysis Revealed the Role of ADAR1 in Pan-Cancer Prognosis and Immune Implications

Jianlin Zhu | Jianjian Zheng | ... | Yan Zhao
  • Special Issue
  • - Volume 2023
  • - Article ID 2516472
  • - Research Article

[Retracted] Exogenous Hydrogen Sulfide Mitigates Oxidative Stress and Mitochondrial Damages Induced by Polystyrene Microplastics in Osteoblastic Cells of Mice

Qingping Shi | Feihong Chen | ... | Wen Wu
  • Special Issue
  • - Volume 2023
  • - Article ID 4397829
  • - Research Article

Endothelial Progenitor Cells Affect the Growth and Apoptosis of Renal Cells by Secreting Microvesicles Carrying Dysregulated miR-205 and miR-206

Yunbo Zhang | Yanling Shen | ... | Shenhong Gu
  • Special Issue
  • - Volume 2023
  • - Article ID 9226712
  • - Research Article

NNMT Is an Immune-Related Prognostic Biomarker That Modulates the Tumor Microenvironment in Pan-Cancer

Wenxiu Liu | Meng Zhu | ... | Shengmian Li
  • Special Issue
  • - Volume 2023
  • - Article ID 5025868
  • - Research Article

lncRNA SSTR5-AS1 Predicts Poor Prognosis and Contributes to the Progression of Esophageal Cancer

Yuhao Hu | Ning Mao | ... | Xiong Deng
  • Special Issue
  • - Volume 2022
  • - Article ID 6832680
  • - Research Article

Study on the Mechanism of miR-125b-5p Affecting Melanocyte Biological Behavior and Melanogenesis in Vitiligo through Regulation of MITF

Xiaochuan Wang | Yifei Wu | ... | Zhiqiong Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 3153362
  • - Research Article

YTHDF2 Regulates Macrophage Polarization through NF-κB and MAPK Signaling Pathway Inhibition or p53 Degradation

Luhui Cai | Di Li | ... | Qimeng Li
  • Special Issue
  • - Volume 2022
  • - Article ID 4607966
  • - Research Article

Ferulic Acid Mitigates Growth and Invasion of Esophageal Squamous Cell Carcinoma through Inducing Ferroptotic Cell Death

Yu Cao | Hong Zhang | ... | Rui Wang

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.